NASDAQ$SKIN
SkinHealth Systems Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter net sales of $81.4 million with year-over-year operating expense improvement.
BeautyHealth's first quarter net sales reached $81.4 million, a decrease of (5.7)% compared to the same period in 2023, with lower equipment sales offset by growth in consumables. The company reported a net loss of $(0.7) million, an improvement from the prior year, and an adjusted EBITDA of $0.4 million.
- Net sales for the first quarter of 2024 were $81.4 million, a decrease of (5.7)% compared to the prior year period, due to lower delivery systems net sales.
- Gross margin was 59.4% in Q1 2024, compared to 62.7% in Q1 2023, with adjusted gross margin at 63.4% versus 70.0% in the prior year.
- Net loss was $(0.7) million in Q1 2024, compared to a net loss of $(20.3) million in Q1 2023, primarily due to the gain on repurchase of convertible notes.
- Adjusted EBITDA was $0.4 million in Q1 2024, compared to adjusted EBITDA of $(0.5) million in Q1 2023, primarily due to lower operating expenses.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$81.4M
Revenue by segment
Beauty Health · $97.4M total across 2 segments · Q3 2023
- Delivery Systems$51M+3.9%52.4%
- Consumables$46.4M+16.9%47.6%
Forward guidance
The company expects second quarter net sales between $96 and $102 million and adjusted EBITDA between $4 and $7 million. For fiscal year 2024, the company anticipates flat to low-single digit % growth in net sales and adjusted EBITDA greater than $40 million.
Tailwinds
- Fiscal year financial guidance reflects a return to net sales growth in the second half of 2024, primarily weighted toward the fourth quarter.
- Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates.
- Excludes any unannounced acquisitions, dispositions or financings.
Headwinds
- Second quarter financial guidance reflects a challenging year-over-year comparison due to the international launch of Syndeo in the comparable 2023 period.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro